Current perspectives on the design of phase II trials of new drugs for the treatment of heart failure.
Packer
M
M
Division of Circulatory Physiology and The Heart Failure Center, Columbia University, New York, NY 10032, USA. mp65@columbia.edu
D002316:Cardiotonic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic / Q000706:statistics & numerical data*; D015195:Drug Design; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D010865:Pilot Projects; D012107:Research Design; D016019:Survival Analysis; D016896:Treatment Outcome
D002316:Cardiotonic Agents; D015507:Drugs, Investigational